Personal Genome Diagnostics (PGDx) is developing tools and technologies to offer patient-specific analysis of the cancer genome. Many cancer patients today are not being tested, or being tested in the window of time that could make a difference to treatment decisions. To unlock a deeper understanding of tumor biology and identify biomarker-informed treatment plans, PGDx uses their portfolio of tissue, liquid-biopsy based genomic products and robust bioinformatics. In this manner, PGDx is removing barriers to precision oncology testing and creating clarity for patients and their clinicians.

Personal Genome Diagnostics

Founded: 2010
Location: Baltimore, MD
Employee range: 50 - 200
Funding: $103M C Feb 2021; $75M Jan 2018

Short description:

Drug notes:

Long description:

Jobs: